Intervacc have now come to a phase where several challenges in clinical trials and manufacturing have been overcome. We see that our main product, Strangvac®, has satisfied expected results in efficacy studies and we have seen that manufacturing of components in the vaccine can be made with a cost effective process. In addition to the remaining steps to launch Strangvac®, we will strengthen the company´s business idea to become a leading company within animal health, which can provide the market with veterinary vaccines and pharmaceuticals.
This means that the company now takes a clear step towards becoming a company with several products rather than only one. We will thus spend further force on the development of a vaccine against a streptococcal infection in piglets. For our subsidiary Nordvacc it means that new distribution agreements recently have been signed and further discussions are presently going on.
External analyzes of the company are conducted by ABG Sundal Collier, among others, and these are presented at Introduce Equity Research.
ABGSC Investor Days
Intervacc participated in ABGSC Investor Day on March 19, 2020 in Stockholm. CEO Andreas Andersson presented the company and the development of a new generation of animal health vaccines. The focus was on Strangvac® and the by EMA recently, confirmed application for marketing authorization which is now validated and ready for review.
Here you can see the recorded presentation which is about 24 minutes including the following Q&A.